Chair, Nativis Medical & Scientific Advisory Board
Director of the Ben & Catherine Ivy Center for advanced Brain Tumor Treatment at Swedish Neuroscience Institute
Charles is The Gregory Foltz, MD Endowed Director of the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Specialists. Charles is a board-certified neurosurgeon who specializes in brain tumors with a combination of hands-on neurosurgery and high-level laboratory research. Prior to joining Swedish, he served as Associate Clinical Professor at UCSF Department of Neurological Surgery, Staff Neurosurgeon at California Pacific Medical Center and Scientist at California Pacific Medical Center Research Institute.
Retired, Professor of Neurology and Neurological Surgery at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance
Marc is Professor of Neurology and Neurological Surgery at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington. Marc has developed many of the methods used today in evaluating and managing neoplastic meningiti. Marc has focused increasingly on clinical trials for primary brain tumors, hoping to achieve new and better therapies. He has published his work in more than 350 scientific papers in peer-reviewed publications, such as the Journal of Neuro-Oncology, Neuro-Oncology, Neurosurgery, Journal of Neurosurgery, Cancer, Neurology, Archives of Neurology, Lancet Oncology, Expert Review of Neurotherapeutics, CNS Oncology, Cancer and Journal of Clinical Oncology. Marc received his medical degree in from Columbia University, College of Physicians and Surgeons in New York.
Patient Care Philosophy
"As a cancer doctor, I think of myself as a patient advocate, and as such, try to provide patients and families with a sense of autonomy and control over their cancer. It’s important to educate patients and families about their cancer to make this frightening and complicated disease more understandable,” says Marc. “Oncologists I believe are meant to provide clarity to patients and families in how we manage and treat cancer. Importantly, I believe that participation by patients with cancer in clinical trials provides an opportunity for novel and hopefully more effective therapy. Consequently, I try whenever available to offer patients and their family investigational clinical trials as part of their choice for cancer treatment."
Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute
Director of Neuro-Oncology, Providence Saint John’s Health Center
Santosh holds a doctorate in molecular biology and is an expert in brain cancer and practices what he terms “human science” – translational research that blends laboratory science and clinical practice to bring innovative, personalized treatment directly to patients.
His research involves immunotherapy, molecular genetics, innovative drug development for cancer stem cells and development of novel biomarker-based clinical trials for cancers. Before joining Providence Saint John's, he was professor of neurosciences at the University of California, San Diego, School of Medicine, and Director of Neuro-oncology at Moores UC San Diego Cancer Center.
A physician and scientist, Santosh develops targeted drug therapies that will advance the treatment of brain tumors to a new level. An estimated 18,000 Americans are diagnosed with primary brain and spine tumors each year. He cares for these patients as well as a large and growing number of patients with metastatic brain tumors originating from cancers in the breast, lung, skin and other sources. Santosh also cares for and studies autoimmune neurological disorders including cancer-related encephalitis as well as direct treatment-related toxicities from radiation and chemotherapy such as chemobrain and peripheral neuropathy.
Founder of the Society of NeuroOncology (SNO)
Emeritus Professor of Neuro-Oncology at The University of Texas, M.D. Anderson Cancer CenterM
Clinical Professor, Department of Neurosurgery, University of California San Francisco Medical School
Victor received his M.D. from the University of Wisconsin-Madison and completed his residency in neurology and NINDS fellowship programs at Massachusetts General Hospital. Prior to residency, he was Staff Associate in the Experimental Therapeutics Branch at the NCI. A world-renown expert in brain tumor research and treatment, he is currently Emeritus Professor of Neuro-Oncology at The UT M. D. Anderson Cancer Center and a past Chairman of the Department of Neuro-Oncology and Director of the Multidisciplinary Brain Tumor Center. He is also a Clinical Professor, Department of Neurosurgery, UCSF Medical School. Victor has authored more than 380 publications including the book, Cancer in the Nervous System, in his 50-year research career.
Prior to 1988, Victor was a professor at UCSF in the Departments of Neurosurgery and Pharmaceutical Chemistry and Chief of the Neuro-Oncology Service of the Brain Tumor Research Center. He is also the founder and first president (1995-97) of the Society for Neuro-Oncology.
Victor is widely respected for pharmacokinetics studies of anticancer drugs in the brain and cerebrospinal fluid, experimental and clinical studies of chemotherapy during radiation therapy, chemotherapy regimens for the treatment of gliomas, and studies of chemotherapy and radiation therapy for childhood medulloblastoma and ependymoma. He has had developed combination chemotherapy and chemoradiation treatments that reflected translation from laboratory to clinic that were successful in clinical trials and investigation. He was also directed the first National Cooperative Drug Discovery Group program to develop inhibitors of the protein tyrosine kinase domain of c-Src between 1983 and 2000. His most recent laboratory research efforts to use reverse phase protein lysate microarrays to understand relative hypoxia and metabolic stress he coupled with new cell-based 2-dimensional and 3-dimensional assays in an effort to speed the development of new drug and drug combinations to selectively inhibit signal transduction pathways critical to tumor proliferation.
Professor-in-Residence and the Charles B. Wilson Chair of Neurosurgery, University of California San Francisco
Program Leader of the Neurological Oncology Program for the Helen Diller Comprehensive Cancer Center at University of California San Francisco
Co-Project Leader, Pacific Pediatric Neuro-Oncology Consortium
Michael began his career in Neuro-Oncology as a Fellow at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and is now Professor-in-Residence and the Charles B Wilson Chair of Neurosurgery. His career interests center around patient care, and clinical and translational research. He became the Project Leader of the North America Brain Tumor Consortium (NABTC) and led that group for 15 years. When the NABTC merged with the NABTT (and became the Adult Brain Tumor Consortium) he was named co-Project Leader until stepping down from this multi-institutional early phase clinical trials group in early 2014. In 2009, he was awarded the Project Leadership of what is called the Ivy Foundation Early Phase Clinical Trials Consortium, a group of now 7 major academic centers who conduct clinical and translation research in adults with brain cancer.
He was the Institutional site Principal Investigator for the Pediatric Brain Tumor Consortium (PBTC) for over 10 years, ending that role in 2012. At that time he formed the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 11 major academic centers across the United States, conducing early phase, precision-focused, clinical trials in young children and adolescents.
Michael is Program Leader of the Neurological Oncology Program for the Helen Diller Comprehensive Cancer Center at UCSF, and for many years was the Director of Translational Research for the Neuro- Oncology program within the Departments Brain Tumor Research Center.
As noted above, his major interests are early phase clinical trials research, and the translational studies that precede and inform those trials in both adults and children. He has published over 300 articles since 1985 in Neuro-Oncology, and is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology.
His greatest award has been the privilege to treat patients with malignant brain tumors, and to be associated with physicians and researchers in the field.
Director, Radich Lab and the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center
Jerald is a Member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center, a Professor of Medicine, and an Adjunct Professor of Pathology at the University of Washington School of Medicine. He is the Director the Radich Lab and the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center. He serves as Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, co-chair of the NCI/NIH Leukemia Steering Committee, and is on the Board of Scientific Counselors, NIH Genome Research Institute. He is the Chair of the CML Committee of the National Comprehensive Cancer Network, a member of the EuroLeukemiaNet CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. His research interests include the molecular genetics of leukemia and the detection of minimal residual disease. The Radich Lab works in close collaboration with the clinical research performed at FHCRC, as well as collaborations with large clinical trials of the Southwest Oncology Group. Jerry earned his M.D. degree from the University of California Davis, School of Medicine.
Chair, Technology Advisory Board
Mike led the early concept and design efforts of Nativis' platform technology, known as Molecular Interrogation and Data Systems (MIDS), pioneering new concepts in signal acquisition, post signal processing, and signal transduction. His career in health care in both the private and public sectors, together with his background in electronics and RF design and engineering, has provided a valuable multidisciplinary framework for enabling and executing innovation within the Company.
Chair, Nativis Medical & Scientific Advisory Board
Endowed Director, The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Institute
Charles is The Gregory Foltz, MD Endowed Director of the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Specialists. Charles is a board-certified neurosurgeon who specializes in brain tumors with a combination of hands-on neurosurgery and high-level laboratory research. Prior to joining Swedish, Charles served as Associate Clinical Professor at UCSF Department of Neurological Surgery, Staff Neurosurgeon at California Pacific Medical Center and Scientist at California Pacific Medical Center Research Institute.
Director, Pre-clinical Development, Nativis
Xavier is the principal scientist for Nativis overseeing pre-clinical research and the application of Nativis technology in multiple disease areas. He has more than 20 years of experience in basic and neurological clinical research, including Alzheimer’s research, neuron biology, cancer research, bioengineering and biophysics.
He has advised emerging biotechnology companies, most notably Cytokinetics and ENG3. Xavier has also served on non-profit Scientific Advisory boards for such organizations as the Brain Health and Healing Foundation and published broadly in multiple areas of science and medicine.
Xavier received his doctoral degree in Neurobiology & Behavior from the University of Washington. His doctoral training was followed by two post-doctoral fellowships within the University of Washington’s Department of Bioengineering. He is currently an affiliate assistant professor in the School of Medicine at the University of Washington.
Independent Pharmaceutical Consultant
Tenured Professor, University School of Medicine at San Antonio
Daniel is an independent pharmaceutical consultant and 30-year veteran of the pharmaceutical and medical device industries with extensive experience at both public and private health care companies. His most recent operating position was president and CEO of Caliper Technologies where he led the company’s development from early stage to a publicly traded commercial organization with two acquisitions. Daniel holds a tenured position at the University of Texas School of Medicine at San Antonio. He received his undergrad from Rutgers University and his medical degree from Georgetown University.
Associate member and Geraldine J. and Robert L. Virgil Distinguished Investigator at the Donald Danforth Plant Science Center
Todd is an associate member and the Geraldine J. and Robert L. Virgil Distinguished Investigator at the Danforth Center. He is part of the team of scientists working in the Enterprise Rent-A-Car Institute for Renewable Fuels. Previously, Todd was Associate Professor at Oregon State University, a member of the Center for Genome Research and Biocomputing and a member of the Molecular and Cellular Biology Program.
Allard Research Professor & Chair, Department of Oncology, University of Alberta
Fellow, National Institute for Nanotechnology of Canada
Jack is an Allard Research Professor and Chair in Experimental Oncology in the Department of Oncology at the University of Alberta. His research interests include computational drug design, systems biology of cancer and neurodegenerative diseases, and pharmacokinetic models. He is a Fellow of the National Institute for Nanotechnology of Canada.
Senior Distinguished Scientist
Gabriel, Distinguished Scientist, is the former Director of Molecular Biology for Dendreon Corporation, former Senior Scientist at Upjohn Company/Pharmacia-Upjohn and Senior Staff Fellow at the National Institutes of Health. Gabriel holds a PhD from the University of Zurich, and was a Postdoctoral Fellow at Yale University.